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Abstract
Background: Intraoperative localization of image or endoscopy-detected lesions occasionally
pose surgical challenges due to the small lesion size and/or difficult anatomic exposure.
Identification of such lesions can be facilitated using a hand-held gamma probe with utilization of
Tc-99m macroaggregate albumen (MAA) localization technique. The radiopharmaceutical injection
can be performed using ultrasound (US) or endoscopy guidance.
Case presentations: The clinical use of the Tc-99m MAA protocol gamma probe-guided surgery
was discussed in three representative cases. Surgical indication was diagnostic exploration in two
patients with suspicious lymphadenopathy, and determination of extent of surgical resection in a
patient with polyposis. Lesion localization with 100 microcurie (3.7 MBq) Tc-99m MAA prior to
surgical exploration resulted in definitive localization of lesions intraoperatively.
Conclusion: The use Tc-99m MAA deposition technique at the site of surgical target is a highly
efficient radio-guided surgery technique with definitive impact on the success of surgical
exploration in selected indications.
Background
The role of gamma probes in surgical oncology practice
has been well established [1-9]. Surgical performance
with intraoperative gamma probe detection is critically
dependent on target to surrounding background ratio
(TBR). This ratio, for localization techniques that involve
systemic administration of radiopharmaceuticals, is a
function of radiopharmaceutical uptake and clearance
kinetics. Probe's ability to discern the target signal also is
a major technical factor in the clinical success. A mini-
mum TBR of 1.5:1 is needed in the operative field for the
operating surgeon to be comfortable that the differences
between the target tissue and normal adjacent tissue are
real [10]. Obtaining a satisfactory TBR is always a signifi-
cant technical challenge with localization techniques
using systemic administration of radiopharmaceuticals.
Administration of a locally-entrapped radiopharmaceuti-
cal in or around the target tissue results in an ideal TBR.
Case presentations
Case 1
A 32 year-old woman with a history of T2-N1 left breast
cancer, diagnosed 2 years ago and treated with mastec-
tomy-immediate reconstruction, presented with a right
axillary lymphadenopathy. Upon clinical exam, the lesion
was non-palpable and measured approximately 1 cm by
US. The lymphadenopathy persisted on a follow-up; FDG-
PET imaging was negative. An US-guided FNA was non-
definitive without evidence of malignancy. An increase in
size of the node was noted at the subsequent follow-up. A
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clinical decision was made for an excision biopsy. The
node was injected with Tc-99m macroaggregate albumen
(MAA) and lymphazurin blue 2 h prior to the planned
operation. At surgery, the hot-spot was readily identified.
Probe localization was distinctly focal over a level-I node,
which was accessed with minimal dissection. Blue dye
facilitated surgical exposure and dissection. Surgical
pathology revealed chronic inflammatory changes (Figure
1).
Case 2
A 65 year-old woman with history of colorectal cancer
(CRC) and non-Hodgkin's lymphoma of the scalp, pre-
sented with mediastinal and retroclavicular lymphaden-
opathy. CRC was diagnosed 2 years ago, and was treated
with R-colon resection. Scalp lymphoma was diagnosed 6
months ago, when the patient presented with a 15 cm
scalp lesion. Staging work-up at that time revealed posi-
tive FDG uptake in the scalp lesion (SUV:18), multiple
mediastinal and R-retroclavicular lymph node (SUV:3.2),
and a 12 cm liver lesion (SUV: 8.5). Biopsy of the liver
lesion was consistent with the colon primary. Nodal find-
ings were concluded to indicate a stage III lymphoma, and
a sequential intensity-modulated radiation therapy
(IMRT) and chemotherapy using CHOP regimen was
administered. There was a complete clinical and FDG-
PET/CT response in the scalp lesion. Post-treatment FDG-
PET/CT showed persistence of mediastinal and R-retrocla-
vicular nodal uptake. The R-retroclavicular node was
injected with Tc-99m MAA and lymphazurin blue 2 h
prior to the planned operation. At surgery, the hot-spot
was readily identified. Probe localization was distinctly
focal over an internal jugular-innominate vein confluence
lymph node. The target was accessed through an incision
made over the hot-spot. The line-of-sight provided a safe
surgical dissection. The blue dye facilitated surgical expo-
sure and dissection. Surgical pathology revealed a chronic
granulomatous disease. The patient was restaged to have a
stage I scalp lymphoma, and remained in complete remis-
sion following treatment. Stage IV CRC was also con-
cluded to be a liver-only disease, which allowed her to be
considered for liver-directed therapy (Figure 2).
Case 3
A 69 year-old man presented with anemia, subsequent
colonoscopy revealed a right colon cancer and multiple
polyps throughout the colon. Severe dysplastic changes
were noted in a sessile polyp in the transverse colon and
in a pedunculated polyp in the sigmoid colon of villous
type. The descending colon polyp was completely excised
colonoscopically and the site was submucosally injected
with Tc-99m MAA and lymphazurin blue 18 h prior to a
planned operation. At surgery, the ascending colon lesion
was readily identified. None of the polyps were palpable.
A slight, relatively diffuse discoloration of submucosal
blue dye was noted at the site of injection. Probe localiza-
tion was distinctly focal. A total abdominal colectomy was
performed with 2-cm margins distal to the focal Tc-99m
a) Right axillary lymphadenopathy demonstrated on mammogram Figure 1
a) Right axillary lymphadenopathy demonstrated on mammogram. b) Ultrasonogram image. The node measures 1 cm and is 
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MAA signal. Surgical pathology confirmed complete
resection with free margins (Figure 3).
Gamma probe-guided surgery protocol
The patients receive an injection of 0.1 mCi (0.037 MBq)
(in 0.1 ml solution) Tc-99m MAA the morning of planned
surgery. Lymph node injections are given most conven-
iently under US. For colon polyp localization, the injec-
tion using the same activity and volume is given
endoscopically. Surgical exploration is scheduled within 6
hours post injection of the radiopharmaceutical. The
injected activity might be doubled if surgery is planned 6–
12 hours after the injection (Table 1). Standard gamma
probe settings (photopeak of 140 keV, Window of 20%,
and a threshold of 136 keV) and operative technique are
used in the operating room.
a) Retroclavicular lymph node demonstrated on composite PET image Figure 2
a) Retroclavicular lymph node demonstrated on composite PET image. b) PET/CT demonstrating large liver lesion. c) Ultra-
sound of lesion.
Table 1: Gamma probe-guided surgery protocol for Tc-99m MAA
Tc-99m MAA Lesion Localization with image/endoscopy guidance
Radiopharmaceutical Dose/Administration • Tc-99m MAA
• 0.1 mCi (.0037 MBq)/direct injection
Standard Imaging Protocol • No nuclear medicine imaging needed
Timing of Surgical Exploration • Within 6 h post-injection
Patient Preparation • Not required
Gamma Probe • Standard medium-energy gamma probe
System set-up • Analyzer Settings: Photopeak: 140 keV, Window: 20%, Threshold: 136 keV (In commercial systems 
this is a default setting)
• Verify calibration and settings of the system
• Cover the probe with sterile plastic sleeve
Intra-operative Use • Probe survey at counts- per-second mode (Dynamic pitch range feed-back helpful)
• Hot-spot confirmation with TBR>1.5 at 10-second count mode (TBR ratio feed-back helpful)
Avoid simultaneous electrocautery useWorld Journal of Surgical Oncology 2007, 5:43 http://www.wjso.com/content/5/1/43
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Discussion
The use Tc-99m MAA deposition technique at the site of
surgical target is a highly efficient radio-guided surgery
technique with definitive impact on the success of surgical
exploration in selected indications. Administration of the
locally-entrapped Tc-99m MAA in or around the target tis-
sue results in an ideal TBR. Tc-99m MAA, when injected
into the tissues, remains almost stationary with a minimal
local diffusion. Particle degradation, slow lymphatic
absorption and phagocytosis constitute the principal
mechanisms for MAA clearance. The biologic half life of
MAA is approximately 6 hours. The effective half life of Tc-
99m MAA is calculated at approximately 3 hours when the
6-hour physical half life of Tc-99m is factored in (1/2 TEff
= 1/2 TBiol + 1/2 TPhys). A 0.1 mCi Tc-99m provides satis-
factory signal intensity for gamma probe detection within
a wide range of time frame. Surgical procedure can be
scheduled any time after injection up to 6 hours. (Sugges-
tion: Surgical procedures can be scheduled any time dur-
ing the 6 hours post injection.) Tc-99m MAA injection can
be given under CT, US or endoscopic guidance. Lymphaz-
urin blue (blue dye) can be added to the injectate to facil-
itate dissection by providing a visual aid.
Conclusion
Major applications of the technique include localization
of lymph nodes and colonic polyps. The technique may
also be used in localization of non-palpable breast lesions
as an adjunct to needle/wire localization techniques.
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A and B) Sigmoid colon polyp and endoscopic injection of the base Figure 3
A and B) Sigmoid colon polyp and endoscopic injection of the base. C) Intaoperative gamma probe localization of Tc-99m MAA 
injection site. D and E) Distribution of multiple polyps in the resected specimen.Publish with BioMed Central    and   every 
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